Day One Biopharmaceuticals Deregisters Securities Following Servier Merger Completion

summarizeSummary

Day One Biopharmaceuticals has filed to deregister all unsold securities from its previous S-3 registration statements, following the completion of its merger with Servier Pharmaceuticals LLC.

check_boxKey Events

• Securities Deregistration

  Day One Biopharmaceuticals has filed Post-Effective Amendments to its S-3 registration statements to deregister all unsold securities.

• Merger Completion

  The deregistration is a direct result of the successful completion of the merger with Servier Detroit Inc., a subsidiary of Servier Pharmaceuticals LLC, on April 23, 2026.

• Termination of Offerings

  As a wholly-owned subsidiary, Day One has terminated all offerings and sales of securities under its previous registration statements, including an equity distribution agreement for up to $250 million.

auto_awesomeAnalysis

This POSASR filing confirms the administrative deregistration of all previously registered securities for Day One Biopharmaceuticals. This action is a direct and necessary consequence of the successful completion of Servier's tender offer and subsequent merger, which resulted in Day One becoming a wholly-owned subsidiary. While the merger itself was the primary market-moving event, this filing formally terminates the company's ability to issue or sell securities under its prior registration statements, marking a definitive end to its life as an independent publicly traded entity.